Vodis Pharmaceuticals, Inc holds the distinction of being one of Canada’s leading medical marijuana companies. With its award-winning grow teams, the company is awaiting a Health Canada inspection for its marijuana license, and has already formed a subsidiary in the US to enter the market in the said country.
Vodis has a marijuana facility in Canada that covers 12,000 square feet, and this is what Health Canada is expected to inspect under the Marihuana for Medical Purposes Regulations (MMPR). Once Vodis is granted its license, the facility may produce 150-200 pounds of medicinal marijuana per month.
Currently, Vodis has 25 strains of medicinal cannabis, cataloged into Indica, Sativa, and Hybrid groups. The company has a subsidiary named Vodis Innovative Pharmaceuticals, which handles and sells these products through its website. As of October 2014, however, its selling is temporarily halted while the company awaits inspection.
On October 2, 2014, Vodis Pharmaceuticals announced that it has formed a wholly owned subsidiary to enter the US marijuana space. Named Vodis USA, Inc, this subsidiary is based in Washington State and will offer real estate to marijuana businesses licensed under the state’s Initiative 502 (I-502). In addition, Vodis plans to license out its manufacturing processes, growing techniques, and other SOPs.
Founded in 2011, Vodis Pharmaceuticals started as Southbridge Resources Corp, a mineral property exploration company in British Columbia. In 2014, as it fully shifted to the pharma industry, it became Vodis Pharmaceuticals, Inc and acquired Vodis Innovative Pharmaceuticals, Inc.
Today, Vodis Pharmaceuticals is traded as VP in the Canadian Securities Exchange. It has a market cap of CAD 18.93 M.
The company is led by CEO Otto Folprecht, alongside President and COO Ivan Millovski, Executive VP Penn Batanov, and VP for Marketing Hani El Rayess.
Vodis Pharmaceuticals, Inc.
#104 – 1037 West Broadway
Vancouver, BC, Canada